Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 11/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20785358 | 0.83 | ADORA2B (0.42) | HPGDALDH1A1TP53ADORA2BADORA2A | |
| SCHEMBL20784800 | 0.77 | DAO (0.39) | HPGDALDH1A1ADORA2BADORA2AMAPT | |
| SCHEMBL21769044 | 0.72 | POLB (0.43) | HPGDALDH1A1TP53ADORA2BADORA2A | |
| SCHEMBL20785200 | 0.70 | ADORA2B (0.58) | ADORA2BADORA2AADORA3ADORA1 | |
| SCHEMBL20784422 | 0.70 | ADORA2B (0.58) | ADORA2BADORA2AADORA3ADORA1 | |
| SCHEMBL20785461 | 0.69 | GLP1R (0.44) | HPGDALDH1A1TP53MAPT | |
| SCHEMBL20784412 | 0.69 | CNR1 (0.36) | ALDH1A1ADORA2BADORA2A | |
| SCHEMBL20772237 | 0.69 | HPGD (0.47) | HPGDALDH1A1TP53MAPT | |
| SCHEMBL21768831 | 0.69 | POLB (0.40) | HPGDALDH1A1ADORA2BADORA2AADORA3 | |
| SCHEMBL1780319 | 0.66 | ADORA2A (0.33) | ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11254686-B1 | Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor | CORVUS PHARMACEUTICALS, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| WO-2019046784-A1 | COMPOUNDS AND METHODS FOR MODULATING ADENOSINE A2B RECEPTOR AND ADENOSINE A2A RECEPTOR | CORVUS PHARMACEUTICALS, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254686-B1 | Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor | ADORA2A, ADORA2B, ADORA3 | HPGD 1246/4885ALDH1A1 665/4885TP53 4094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.